Neuren Pharmaceuticals Limited

ASX:NEU 株式レポート

時価総額:AU$2.1b

Neuren Pharmaceuticals マネジメント

マネジメント 基準チェック /34

Neuren Pharmaceuticalsの CEO はJon Pilcherで、 May2020年に任命され、 の在任期間は 4.5年です。 の年間総報酬はA$ 1.36Mで、 40.2%給与と59.8%のボーナス(会社の株式とオプションを含む)で構成されています。 は、会社の株式の0.31%を直接所有しており、その価値はA$ 6.59M 。経営陣と取締役会の平均在任期間はそれぞれ4.4年と6.3年です。

主要情報

Jon Pilcher

最高経営責任者

AU$1.4m

報酬総額

CEO給与比率40.2%
CEO在任期間4.5yrs
CEOの所有権0.3%
経営陣の平均在職期間4.4yrs
取締役会の平均在任期間6.3yrs

経営陣の近況

Recent updates

New Forecasts: Here's What Analysts Think The Future Holds For Neuren Pharmaceuticals Limited (ASX:NEU)

Nov 11
New Forecasts: Here's What Analysts Think The Future Holds For Neuren Pharmaceuticals Limited (ASX:NEU)

Neuren Pharmaceuticals Limited's (ASX:NEU) Shares Climb 26% But Its Business Is Yet to Catch Up

Nov 08
Neuren Pharmaceuticals Limited's (ASX:NEU) Shares Climb 26% But Its Business Is Yet to Catch Up

Calculating The Intrinsic Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Oct 24
Calculating The Intrinsic Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models

Aug 29
Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models

Pinning Down Neuren Pharmaceuticals Limited's (ASX:NEU) P/S Is Difficult Right Now

Aug 14
Pinning Down Neuren Pharmaceuticals Limited's (ASX:NEU) P/S Is Difficult Right Now

Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today

May 31
Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today

Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely

May 03
Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely

An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued

Apr 01
An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued

Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically

Mar 05
Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically

Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors

Mar 02
Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors

Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors

Dec 18
Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors

Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues

Sep 02
Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues

Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Aug 31
Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year

Mar 03
This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year

Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business

Jan 07
Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Sep 06
We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth

May 31
Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth

We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn

Feb 03
We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn

Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation

Aug 06
Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

May 05
We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)

Feb 19
Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)

Have Insiders Been Selling Neuren Pharmaceuticals Limited (ASX:NEU) Shares This Year?

Jan 04
Have Insiders Been Selling Neuren Pharmaceuticals Limited (ASX:NEU) Shares This Year?

CEO報酬分析

Neuren Pharmaceuticals の収益と比較して、Jon Pilcher の報酬はどのように変化したか?
日付総報酬給与会社業績
Jun 30 2024n/an/a

AU$117m

Mar 31 2024n/an/a

AU$137m

Dec 31 2023AU$1mAU$549k

AU$157m

Sep 30 2023n/an/a

AU$106m

Jun 30 2023n/an/a

AU$55m

Mar 31 2023n/an/a

AU$28m

Dec 31 2022AU$546kAU$396k

AU$184k

Sep 30 2022n/an/a

-AU$3m

Jun 30 2022n/an/a

-AU$7m

Mar 31 2022n/an/a

-AU$7m

Dec 31 2021AU$432kAU$203k

-AU$8m

報酬と市場: Jonの 総報酬 ($USD 890.72K ) は、 Australian市場 ($USD 1.44M ) の同様の規模の企業の平均を下回っています。

報酬と収益: Jonの報酬は過去 1 年間で 20% 以上増加しました。


CEO(最高経営責任者

Jon Pilcher

4.5yrs

在職期間

AU$1,364,404

報酬

Mr. Jonathan Charles Pilcher, also known as Jon, BSc (Hons), ACA, FCA serves as Managing Director & Executive Director at Neuren Pharmaceuticals Limited since June 14, 2021. He had been a Company Secretary...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Jonathan Pilcher
CEO, MD & Executive Director4.5yrsAU$1.36m0.31%
A$ 6.6m
Lauren Frazer
CFO & Company Secretary4.3yrsデータなしデータなし
Lawrence Glass
Chief Science Officer20.8yrsデータなしデータなし
Gerry Zhao
Vice President of Corporate Developmentno dataデータなしデータなし
Liza Squires
Chief Medical Officer2.3yrsデータなしデータなし

4.4yrs

平均在職期間

経験豊富な経営陣: NEUの経営陣は 経験豊富 であると考えられます ( 4.4年の平均在職年数)。


取締役

名称ポジション在職期間報酬所有権
Jonathan Pilcher
CEO, MD & Executive Director3.4yrsAU$1.36m0.31%
A$ 6.6m
Dianne Angus
Independent Non-Executive Director6.3yrsAU$75.00k0.023%
A$ 496.2k
Jenny Harry
Independent Non-Executive Director6.3yrsAU$75.00k0.023%
A$ 490.7k
Patrick Donald Davies
Independent Non-Executive Chairman6.3yrsAU$125.00k0.21%
A$ 4.4m
Joe Basile
Independent Non-Executive Director1.7yrsAU$62.50k0.017%
A$ 354.1k

6.3yrs

平均在職期間

経験豊富なボード: NEUの 取締役会経験豊富 であると考えられます ( 6.3年の平均在任期間)。